Not for use with other long-acting β 2-agonists. Do not exceed recommended dose. Prescribe a short-acting, inhaled β 2-agonist for acute symptoms; monitor for increased need. Monitor for signs ...

Developed with US respiratory specialist firm Innoviva, the drug (known as Breo Ellipta in the US ... not adequately controlled on low or medium dose inhaled corticosteroids.

GSK is aiming to revive its respiratory drugs franchise with drugs such as Trelegy, a triple therapy that aims to provide a more convenient single daily dose ... Relvar/Breo Ellipta and Anoro ...

Efforts to supplant pressurised metered-dose inhalers (pMDIs) with DPIs, most recently by the European Network ... Meanwhile GSK's lead inhalers include Trelegy Ellipta, projected to bring $3.3bn in ...